Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
Aug 27, 2024
- Pharmaceuticals
- R&D
Roche’s Announcement regarding PiaSky (Approval in the EU for the Treatment of People with PNH)
TOKYO, August 27, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a Media Release regarding the Chugai originated pH-dependent binding humanized anti-complement (C5) monoclonal antibody PiaSky® (generic name: crovalimab (genetical recombination)). The European Commission (EC) has approved PiaSky for the treatment of adults and adolescents (12 years of age or older with a weight of 40 kg and above) with paroxysmal nocturnal hemoglobinuria (PNH) who are new to and have been previously treated with C5 inhibitors.
Please refer to the link below for details of the Roche’s Media Release:
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
https://www.roche.com/media/releases/med-cor-2024-08-27
